FindTrial
Sign In

Clinical evaluation of desuzumab in the treatment of femoral head necrosis

Clinical evaluation of desuzumab in the treatment of femoral head necrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061164
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteonecrosis of femoral head

Interventions

experience group:Desuzumab

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Mont and the clinical diagnosis and treatment guidelines for adult femoral head necrosis (2020); 2. According to the stage standard of femoral head necrosis in Arco 2019, patients with Arco stage I - II were included; 3. Having complete clinical and imaging data; 4. Adults over 18; 5. Patients treated with desuzumab.

Exclusion criteria

Exclusion criteria: 1. Accompanied by serious chronic diseases, cardiovascular and cerebrovascular diseases, liver and kidney insufficiency, lung diseases, etc; 2. Accompanied by other joint injuries, fractures, severe infections, etc; 3. Accompanied by malignant tumors, blood system diseases, autoimmune system diseases, mental diseases, etc.

Design outcomes

Primary

MeasureTime frame
Collapse rate of femoral head;Total hip replacement rate;bone density;—

Secondary

MeasureTime frame
Harris score;—

Contacts

Public ContactYirong Zeng

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

hywi0419@163.com+86 13711456292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026